SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-007155
Filing Date
2019-08-06
Accepted
2019-08-06 09:16:14
Documents
57
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20190630x10q.htm 10-Q 1671809
2 EX-31.1 btai-20190630ex31183cfdc.htm EX-31.1 22047
3 EX-31.2 btai-20190630ex3122cd407.htm EX-31.2 21713
4 EX-32.1 btai-20190630ex3214e02e6.htm EX-32.1 12349
5 EX-32.2 btai-20190630ex3228f87ec.htm EX-32.2 10756
  Complete submission text file 0001558370-19-007155.txt   4435359

Data Files

Seq Description Document Type Size
6 EX-101.INS btai-20190630.xml EX-101.INS 606745
7 EX-101.SCH btai-20190630.xsd EX-101.SCH 35337
8 EX-101.CAL btai-20190630_cal.xml EX-101.CAL 33129
9 EX-101.DEF btai-20190630_def.xml EX-101.DEF 104007
10 EX-101.LAB btai-20190630_lab.xml EX-101.LAB 302733
11 EX-101.PRE btai-20190630_pre.xml EX-101.PRE 233756
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 191000600
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences